CIPDB › China Industry › Chemicals › Pharmaceutical Intermediate
China, Chinese CAS 2381089-83-2 Lyophilized Powder 99% Weight Loss GLP-1 Retatrutide1 Industrial Products Supplier Manufacturer Details, price list catalog:
China Products Details Supplier Manufacturer price list catalog
Pharmaceutical IntermediatePeptide RetatrutideRetatrutide
Xi'an Harmonious Natural Biotechnology Co., Ltd.
Preview:
Product Description CAS 2381089-83-2 Lyophilized Powder 99% Weight Loss GLP-1 RetatrutideProduct DescriptionProduct NameRetatrutideAppearanceWhite PowderAssay99%CAS2381089-83-2MW4731.33Detailed Photos Retatrutide is a triple agonist peptide that can activate glucagon receptor (GCGR), glucose dependent insulinotropic polypeptide receptor (GIPR), and glucagon like peptide-1 receptor (GLP-1R).Retatrutide (LY3437943) acetate is a triple agonist peptide of glucagon receptor (GCGR), glucose dependent insulinotropic polypeptide receptor (GIPR), and glucagon like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R, with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. Retatrutide acetate exhibits activity against GCGR, GIPR, and GLP-1R in mice, with EC50 values of 2.32, 0.191, and 0.794 nM, respectively. Retatrutide (LY3437943) acetate participates in GCGR in vivo and can improve glucose tolerance in ipGTT through GIP or GLP-1 receptors. Retatrutide acetate activates glucagon receptors, leading to significant weight loss and increased energy expenditure. Retatrutide acetate can be used for research on obesity.Installation InstructionsRetatrutide (LY3437943) is a triple agonist peptide that can simultaneously activate glucagon receptor (GCGR), glucose dependent insulinotropic polypeptide receptor (GIPR), and glucagon like peptide-1 receptor (GLP-1R).The main pharmacological effects of Retatrutide are as follows:Retarutide acetate exhibited activity at EC50 values of 5.79, 0.0643, and 0.775 nM, respectively, by inhibiting human GCGR, GIPR, and GLP-1R.In a mouse model, Retarutide acetate exhibited similar activity with EC50 values of 2.32, 0.191, and 0.794 nM for GCGR, GIPR, and GLP-1R, respectively.Through activation of glucagon receptors, Retarutide acetate can lead to significant weight loss and increased energy expenditure, making it potentially valuable for obesity research.In vivo, Retatrutide participates in GCGR and can improve glucose tolerance in ipGTT through GIP or GLP-1 receptors.Clinical studies have shown that Retatrutide can help obese patients lose an average of 24% of their weight within 48 weeks, which is one of the largest weight loss effects seen so far.In addition, Retatrutide has shown effects in lowering blood pressure and improving blood glucose control. In patients with pre diabetes, nearly three quarters of patients have reached normal blood sugar levels by 48 weeks. Biological ActivityRetatrutide (LY3437943), a single peptide conjugated to a lipid diacid molecule, exerts a powerful agonist effect on the human glucagon‐receptor (GCGR), GIPR, and GLP‐1R. In comparison with the human glucagon and glucagon‐like peptide 1 (GLP‐1), retatrutide exhibits reduced potency (by a factor of 0.3 and 0.4, respectively) on the GCGR and GLP‐1R while displaying enhanced potency at the human GIPR (by a factor of 8.9) when compared to the glucose‐dependent in-sulinotropic polypeptide (GIP)[7]. Mechanism of actionWhen injected into mice suffering from diabetes-induced kidney injury, retatrutide was found to markedly reduce albuminuria levels while also increasing renal filtration rate. This was attributed to its ability to activate GLP-1R/GR-dependent signalling pathways, which then produced anti-inflammatory and antiapoptotic effects that protected the kidneys from further damage. Additionally, it has been shown to directly modulate glomerular permeability, thus leading to improved urinary concentration. Initial results indicate that the peptide can induce marked improvements in albuminuria levels within just four weeks of treatment when compared to other treatments for chronic kidney disease such as ACE inhibitors or angiotensin receptor blockers (ARBs). Moreover, retatrutide has demonstrated a greater effect than either ACE inhibitors or ARBs at reducing systolic blood pressure without inducing significant side effects. Side effectsThe most common side effects of retatrutide are gastrointestinal, including: Nausea, Diarrhea, Vomiting, and Constipation. At higher doses, researchers stated these symptoms were "mostly mild to moderate in severity" and typically treated by lowering the dosage. However, 7% of patients also experienced skin tingling. At 24 weeks of treatment, patients' heart rates on higher doses peaked but declined afterward.CertificationsCompany Profile
Purchasing Agent
Note: Send your message to supplier or manufacturer.
Welcome to our Professional and comprehensive procurement services...